Viatris leadership interviews test whether candidates understand how directing a global generics and off-patent branded pharmaceutical company through post-combination integration and strategic portfolio rationalization differs from leading an innovator pharmaceutical company or a standalone generic manufacturer – where CEO Scott Smith, who succeeded Michael Goettler in June 2023, inherited the charge of executing Viatris's deleveraging commitment from approximately $14 billion gross debt at the November 2020 Mylan-Upjohn combination close, accelerating portfolio focus through decisions including the November 2022 biosimilar business divestiture to Biocon Biologics that generated approximately $3.3 billion and allowed debt reduction while simplifying the business toward complex generics and off-patent branded products, and establishing a coherent Viatris organizational identity that is neither the aggressive generic challenger Mylan was nor the big-pharma governance structure Pfizer Upjohn represented. Leadership at Viatris spans post-combination integration governance and culture-building (where creating a functional Viatris organization from two predecessor companies with incompatible operating models, compensation structures, and cultural values required organizational design decisions about centralization versus decentralization, role consolidation, and identification of the cultural elements from each predecessor that create competitive advantage in a generic pharmaceutical business versus those that must be redesigned), strategic portfolio rationalization and capital allocation (where Viatris's portfolio of approximately 1,400 molecules across complex generics, branded generics, and branded off-patent products required leadership decisions about which product categories merit continued investment versus which are best monetized or divested as the deleveraging imperative constrains available capital), international market leadership across 165 countries (where Viatris's operations in markets ranging from the United States and Germany to India, China, and dozens of emerging markets require leaders who can manage the organizational complexity of a truly global pharmaceutical company while maintaining the cost discipline that a generics business requires), and stakeholder management across debt capital markets, rating agencies, and the employee base inherited from both predecessor companies.

Start your free Viatris Leadership practice session.

What interviewers actually evaluate

Post-Combination Integration Governance, Portfolio Rationalization, and Deleveraging Leadership

Viatris leadership interviews probe whether candidates understand how pharmaceutical executive leadership differs from industrial or consumer company leadership in the post-combination integration challenge (the Mylan-Upjohn combination created not just a combined organizational chart but two distinct pharmaceutical operating philosophies that required resolution – where Mylan executives had built careers on aggressive patent challenges, cost discipline, and entrepreneurial generic drug commercialization while Upjohn executives came from Pfizer's structured governance model with premium compensation, established compliance programs, and risk-averse decision frameworks, and where the leadership task of building a functional Viatris required choosing between these philosophies at every organizational decision point rather than simply combining the two organizations and hoping cultural alignment would follow), the portfolio rationalization discipline (Viatris's strategic clarity as a complex generics and off-patent branded pharmaceutical company required leadership decisions to exit businesses that, while growing, consumed capital and management attention incompatible with the deleveraging priority – where the biosimilar divestiture to Biocon represented a leadership decision to monetize a future-oriented business at a time when that future required investment Viatris's balance sheet could not support, and where evaluating similar rationalization decisions across 1,400 molecules requires a disciplined investment framework that prioritizes cash generation and ANDA pipeline returns over revenue growth at the expense of debt reduction), and the international organizational complexity (managing a pharmaceutical company across 165 countries requires leaders who understand how to structure an operating model that provides policy consistency and governance without creating the organizational overhead that a generics business cost structure cannot support, where the balance between centralized global functions and local market autonomy determines whether Viatris can maintain competitive cost structure while complying with local employment laws, regulatory requirements, and commercial market dynamics in dozens of distinct markets).

The debt capital markets relationship creates a leadership accountability specific to Viatris's post-combination financial position: the approximately $14 billion gross debt at combination close required management to demonstrate credible deleveraging progress to rating agencies and debt investors who were assessing whether Viatris's cash generation could service the obligation while maintaining the investment and operating costs of a global pharmaceutical business, and where quarterly earnings communications required transparent reporting on deleveraging progress, free cash flow generation, and the portfolio rationalization steps being taken to support debt reduction.

What gets scored in every session

Specific, sentence-level feedback.

Dimension What it measures How to answer
Post-combination integration governance and cultural design Do you understand how to lead the organizational integration of Mylan and Upjohn into a functional Viatris – how to assess which cultural elements from each predecessor create competitive advantage in the combined generic pharmaceutical business versus which represent incompatible operating assumptions that must be resolved through designed Viatris values rather than waiting for organic cultural convergence, what the organizational design decisions are about centralized versus decentralized functions that reflect Viatris's strategy as a cost-conscious global generics company, and how to manage the retention of executives and key employees from both predecessor organizations who are evaluating whether the combined Viatris offers a career environment comparable to what they valued at Mylan or Upjohn? We flag leadership answers that describe post-merger integration as communication campaigns and town halls without engaging with the organizational design decisions and cultural value trade-offs that determine whether the combined company develops a coherent identity or remains two cultures occupying the same legal entity. Cultural assessment and design framework, organizational centralization decisions for global generic pharma, key executive retention investment criteria
Strategic portfolio rationalization and capital allocation discipline Can you describe how to develop Viatris's capital allocation framework for a portfolio of 1,400 molecules under a deleveraging constraint – how to evaluate the biosimilar business divestiture decision against the revenue and pipeline contribution the biosimilar segment provided before concluding that monetization served the strategic priority better than continued internal investment, what the criteria are for identifying additional product categories or geographic markets where divestiture or licensing generates debt reduction proceeds at an acceptable strategic cost, and how to communicate the portfolio rationalization strategy to investors who may view asset sales as evidence of strategic retreat rather than disciplined capital allocation? We score whether your portfolio analysis engages with the specific trade-off between growth investment and deleveraging that defines Viatris's capital allocation context rather than generic capital allocation frameworks that do not reflect the post-combination debt constraint. Divestiture criteria development, deleveraging-constrained capital allocation, investor communication of rationalization strategy
International organizational model design across 165 countries Do you understand how to design the organizational model for a pharmaceutical company operating in 165 countries – how to determine which functions should be centralized in global centers of excellence versus maintained at the country or regional level to comply with local employment law, regulatory requirements, and commercial market dynamics, what the governance framework is for making decisions that affect operations in multiple countries with different legal and regulatory environments, and how to build the management talent pipeline in emerging markets where Viatris's branded generic portfolio requires local pharmaceutical commercial expertise that cannot be developed purely from the central organization? We detect leadership answers that describe global organizational design as standardizing processes across all countries without engaging with the regulatory compliance and local market adaptation requirements that force genuine localization rather than global policy enforcement. Global versus local function allocation decisions, country-level governance framework, emerging market leadership development
Debt capital markets communication and deleveraging credibility management Can you describe how to maintain credibility with rating agencies and debt investors during Viatris's multi-year deleveraging from approximately $14 billion gross debt – what the quarterly communication framework is for demonstrating deleveraging progress through free cash flow generation, debt repayment, and asset monetization against the commitments made at combination close, how to manage the investor communication when deleveraging progress in a given period falls short of expectations due to pharmaceutical market pricing pressure or currency headwinds that affect reported results, and what the relationship management approach is with rating agency analysts who are assessing Viatris's commitment to reaching investment-grade leverage ratios within a credible timeframe? We flag leadership answers that treat debt capital markets communication as investor relations messaging without engaging with the specific deleveraging metrics and timeline commitments that determine whether rating agencies maintain or downgrade Viatris's credit rating during the post-combination period. Free cash flow to debt repayment communication, deleveraging shortfall explanation framework, rating agency relationship management

How a session works

Step 1: Choose a Viatris leadership scenario – post-combination integration governance and cultural design, strategic portfolio rationalization and capital allocation under deleveraging constraint, international organizational model design across 165 countries, or debt capital markets communication and deleveraging credibility management.

Step 2: The AI interviewer asks realistic Viatris leadership questions: how you would structure the governance process for deciding whether Viatris should pursue a divestiture of its generics business in a specific European market where the combined Mylan-Upjohn portfolio has significant overlap with local generic manufacturers and where achieving sustainable profitability requires either scale investment or exit, including what the financial analysis framework is for evaluating exit versus continued operation, how to assess the strategic value of the European market presence beyond its standalone financial contribution, and what the stakeholder consultation process looks like for a decision that affects hundreds of local employees and requires regulatory notification in European markets where works council consultation rights apply; how you would lead the Viatris response when a major rating agency places Viatris on negative credit watch citing slower-than-expected deleveraging progress in the context of pharmaceutical pricing pressure in the US generic market and currency headwinds reducing the dollar value of European earnings, including what the immediate communication strategy is to prevent market overreaction, what the operational levers are for accelerating free cash flow generation in the near term, and how to engage the rating agency analysts with updated financial projections that demonstrate a credible path to the leverage ratio target within an acceptable timeframe; or how you would develop the leadership succession framework for Viatris's country manager roles across 30 emerging markets where the former Upjohn branded generic portfolio is the primary revenue driver, including how to identify the leadership capabilities most predictive of success in managing branded generic businesses in price-competitive markets, what the development investment is for high-potential local leaders versus the decision to recruit from the external pharmaceutical talent market in each country, and how to structure the performance management framework for country managers whose results are significantly influenced by currency movements and local healthcare reimbursement policy changes outside their control.

Step 3: You respond as you would in the actual interview. The system scores your answer on post-combination integration governance, portfolio rationalization discipline, international organizational design, and debt capital markets leadership.

Step 4: You get sentence-level feedback on what demonstrated genuine pharmaceutical executive leadership understanding and what needs stronger deleveraging strategy specificity or post-combination integration depth.

Frequently Asked Questions

Who is Viatris's current CEO and what is his strategic agenda?
Scott Smith became Viatris's CEO in June 2023, succeeding Michael Goettler who had led the company since its formation through the Mylan-Upjohn combination in November 2020. Smith's leadership agenda focuses on completing the deleveraging commitment from Viatris's high post-combination leverage ratio, maintaining the portfolio rationalization discipline that the biosimilar business divestiture to Biocon Biologics represented, and executing the strategy of Viatris as a focused complex generics and off-patent branded pharmaceutical company with global scale. The leadership transition itself represented a governance decision by Viatris's board to bring in a leader whose operational discipline and cost management orientation fit the company's priority of generating sustainable free cash flow for debt reduction rather than revenue growth investment.

Why did Viatris divest its biosimilar business and what did the divestiture signal about strategy?
The November 2022 divestiture of Viatris's biosimilar business to Biocon Biologics for approximately $3.3 billion in cash and equity was a portfolio rationalization decision that reflected the tension between biosimilar development's capital requirements and Viatris's deleveraging priority. Biosimilar products require clinical development investment that competes with debt reduction for the free cash flow that Viatris's approximately $14 billion gross debt demands. Beyond the financial calculus, the divestiture signaled strategic clarity: Viatris would be a complex generics and off-patent branded pharmaceutical company rather than a biosimilar developer, allowing management focus on the ANDA pipeline, the international branded generic portfolio, and the operational efficiency that a cost-competitive generic pharmaceutical business requires.

How does leading a post-combination pharmaceutical company differ from leading a standalone organization?
Post-combination pharmaceutical leadership requires managing two simultaneous challenges that standalone leadership does not face: the organizational integration task of creating a functional combined company while maintaining operational continuity in the business, and the financial obligation of managing the leverage incurred to finance the combination while investing sufficiently in the combined operations to maintain competitiveness. The Mylan-Upjohn combination created a company with incompatible predecessor cultures, duplicate organizational structures, and different governance standards that required active leadership resolution rather than passive organizational evolution. Leaders who have not managed post-combination integration often underestimate the time and attention that organizational design decisions, culture assessment, and key employee retention require in the years immediately following a major pharmaceutical combination.

What is Viatris's international leadership model across 165 countries?
Viatris operates in 165 countries with a tiered organizational model where global functional leaders set policy frameworks and governance standards while regional and country-level leaders manage commercial operations, regulatory compliance, and employment relationships in their markets. The leadership challenge in managing this model is determining which decisions require global consistency versus local adaptation – where pricing decisions, product portfolio management, and manufacturing quality standards benefit from global coordination while market access strategies, customer relationships, and employment practices require genuine local leadership authority. Viatris's emerging market operations, where the former Upjohn branded generic portfolio drives significant revenue, require country leaders with deep local pharmaceutical market knowledge and healthcare system relationships that cannot be managed effectively from a global headquarters.

How does Viatris's deleveraging commitment affect leadership decision-making?
The approximately $14 billion gross debt at combination close created a capital allocation constraint that shapes leadership decisions across Viatris's operations: investment proposals that would be approved at a company with an investment-grade balance sheet face higher hurdle rates at Viatris, where free cash flow is prioritized for debt reduction before growth investment. The deleveraging commitment also creates external accountability to rating agencies and debt investors who monitor quarterly progress against deleveraging targets and who assess whether management's operational decisions reflect the financial discipline the debt obligation requires. Leaders at Viatris must understand how to operate a complex global pharmaceutical business while maintaining the cost discipline and free cash flow generation that the deleveraging timeline demands.

Also practice

One full session free. No account required. Real, specific feedback.